4th Quarter - Report
INTEGRATED SOLUTIONS GROUP for TEVA PHARMACEUTICALS USA
Client
Income
$40,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
S.1882, Fair and Immediate Release of Generic Drugs Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| MOSES BOYD | Counsel, Senate Commerce Committee |
| G JOHN O'HANLON | — |
Health Issues HCR
Monitored legislation concerning promotion of generic drug use and medicaid Drug Shortages, Forfeiture and FDA regulations H.R. 5651 Food and Drug Administration Reform Act of 2012 H.R. 4332 Generic Drug Application Review Fairness Act of 2012 S.3187, Food and Drug Administration Act S.27 Preserve Access to Affordable Generics Act S.1882 Fair and Immediate Release of Generic Drug Act "Plan B" Policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| MOSES BOYD | Counsel, Senate Commerce Committee |
| G JOHN O'HANLON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.